Filing Flows › Adma Biologics (ADMA) › Q3 2026
Adma Biologics (ADMA) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Adma Biologics (ADMA) reported revenue of $141M for the third quarter 2026 (Q3 2026), +5% from a year earlier and +13% from the quarter before. Operating margin was 48.0%, net earnings $49.9M (35.4% of revenue).
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $141M | +13% | +5% |
| Gross profit | $99.9M | +16% | +32% |
| Operating profit | $67.8M | +29% | +33% |
| Net earnings | $49.9M | +32% | +37% |
| Operating cash flow | $17.4M | -41% | +31% |
| Free cash flow | $15.4M | -44% | — |
What changed
Revenue was $141.1M in Q3 2026, up 5% year over year and up 13% from the previous quarter.
Gross margin was 70.8%, up 14.5 points from Q3 2025. Operating profit was $67.8M, a 48.0% margin (up 10.0 points year over year). Of the extra revenue versus Q3 2025, 243% reached operating profit, above the 38% margin then. Operating expenses grew 31% against revenue growth of 5%. The fastest-growing cost line was Research & development (+194%). Net earnings were $49.9M, up 37% year over year. The effective tax rate was 24.0%.
Operating cash flow was $17.4M (up 31% year over year), 35% of net earnings. Non-cash charges added back $1.7M of depreciation and amortization and $6.2M of share-based compensation. Working capital and other items used $40.4M. Capital expenditures of $2.0M left free cash flow of $15.4M.
Questions
What was Adma Biologics' revenue in the third quarter 2026?
Adma Biologics (ADMA) reported revenue of $141M for the third quarter 2026 (Q3 2026), +5% from a year earlier and +13% from the quarter before.
Was Adma Biologics profitable in the third quarter 2026?
Operating profit was $67.8M (48.0% of revenue) and net earnings $49.9M.
Source: Adma Biologics 10-Q on SEC EDGAR.